Uterine cancer is one of the most common gynecologic malignancy among female cancer patients. This uterine cancer is of two types: endometrial cancer and uterine sarcoma. Endometrial cancer is caused due to uncontrolled growth of inner linings of uterus. Endometrial cancer is often curable, however, uterine sarcoma is rare cancer, which develops in the muscle and supporting tissues of the uterus (womb). According to National Cancer Institute, Megestrol Acetate is only drug approved by U.S. Food and Drug Administration (FDA) for the treatment of endometrial cancer till March 2016. Diagnosis of both types of uterine cancer is done through endometrial biopsy, colposcopy or Pap smear screening test.
Uterine Cancer Drugs Market Drivers
Increasing funding for cancer research, rising insurance coverage, and increasing number of new targeted cancer drugs are supporting the revenue growth of uterine cancer drugs market size. For instance, National Cancer Institute, in 2015, invested around US$ 4,480 million on cancer research, which include uterine cancer, cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, and ovarian cancer. Furthermore, according to the American Cancer Society, U.S. has spent around US$ 87.8 billion in 2014, on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.
Chemotherapy is the most recommended therapy suggested for treatment of uterine sarcomas. However, chemotherapy may not work in certain types of uterine sarcoma. Chemotherapy for uterine sarcoma is often conducted in the earlier stages of cancer. Various chemotherapy drugs used in the treatment of uterine sarcoma include Paclitaxel (Taxol), Docetaxel (Taxotere), Dacarbazine (DTIC), Liposomal doxorubicin (Doxil), Epirubicin (Ellence), and among others.
Furthermore, increasing number of clinical trials conducted for treatment of endometrial cancer and uterine sarcoma are expected to augment growth of the uterine cancer drugs market. According to U.S. National Library of Medicine, August 2017, clinical trials database, Memorial Sloan Kettering Cancer Center: a cancer treatment and research institute in New York, is engaged in conducting two clinical trial studies for uterine cancer, which includes Phase II study of Nivolumab immunotherapy to treat recurrent or persistent uterine cancer and second is the Selinexor (KPT-330) with Paclitaxel and Carboplatin, present in phase I clinical stage for treating advanced ovarian and endometrial cancers.
Increasing incidence rate of uterine cancer, increasing research and development studies by various government and private research organizations to develop effective drugs for the treatment of endometrial cancer and uterine sarcoma are expected to propel growth of the uterine cancer drugs market in near future. For instance, according to the American Cancer Society, January 2018, around 63,230 new cases of uterine cancer are estimated to be diagnosed the in U.S. and around 11,350 women are expected to die from uterine cancer in 2018. These estimates includes both endometrial cancers and uterine sarcomas and in most of the times, upto 8% of uterine body cancers are sarcomas. According to the same source, endometrial cancer majorly affects post-menopausal women, with the average age of 60 years. According to the Cancer Research UK, in 2015, uterine cancer is the fourth most common cancer among the women’s in the U.K. with around 9,000 new cases in 2015. Furthermore, uterine cancer accounted for 5% of all new cancer cases in females in the UK for the same year (2015).
Uterine Cancer Drugs Market - Regional Analysis
Geographically, uterine cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. According to World Health Organization (WHO) 2018 data findings, cervical cancer is the fourth most frequent type of cancer in women, which accounted for an estimated 530,000 new cases in 2012, representing 7.9% of all female cancers. Furthermore, according to WHO: 2018, around 90% the 270,000 deaths from cervical cancer in 2015 are occurred in low- and middle-income countries. Furthermore, the prevalence of endometrial cancer is higher in developed economics such as the in North America and the Europe, owing to changing lifestyles of women in these countries. The prevalence of uterine cancer is more common in women aged 50 years and above.
Thus, uterine cancer drugs market is expected to exhibit significant growth in North America and Europe region, followed by Asia Pacific region. North America holds dominant position in uterine cancer drugs market, owing to the increasing incidence rate of endometrial cancer cases in these region. For instance, according to the International Agency for Research on Cancer: 2014 data findings, published by World Cancer Research Fund International, in January 2015, around 53% of the endometrial cancer cases were reported in developed economies, which includes U.S., Luxemburg, Norway, Poland, and among others. Moreover, according to the same source incidence of endometrial cancer was fond to be highest in Northern America and Europe and the lowest incidence in Africa and Asia. Furthermore, according to the data published in Journal of the National Cancer Institute in April 2018, North America, Eastern, and Northern Europe witnessed highest rate of endometrial cancer incidence and lowest rate were reported in middle-income countries including South Africa and India.
Uterine Cancer Drugs Market Competitive Landscape
Some of the key players operating in the uterine cancer drugs market include Merck & Company, Inc., Actiza Pharmaceutical Private Limited, United Biotech Pvt Ltd, Elder Pharmaceuticals Ltd, Par Pharmaceutical Companies, Inc. and among others.
Uterine Cancer Drugs Market Taxonomy:
By Product Type:
By Distribution Channel: